

14 February 2023



The Nifty ended 0.89% up at 17929.85. It opened on a positive note and moved up towards ending in green. The benchmark Index yet to breakout massive resistance placed in the price range of 17950-18000 levels. hence, staying cautious on rise is advised. The Nifty immediate range likely to be 17650-18000 with a negative bias.

On the Nifty hourly chart, pullback against ongoing retracement may find sellers on rise around the critical MA band placed in the price range of 17950-18000. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; weakness likely to sustain as long as it trades below 17950-18000. Stock specific retracement likely to continue, which may take the Benchmark Index towards 17500 again.

Nifty Crucial Supports & Resistances-

Supports- 17650, 17500 Resistances- 17950, 18000

Open Positional Calls-

T+30 INST POSITIONAL SELL-
| Fut Segment | TVS MOTOR @
1050-1060, TGT- 960, Closing SL-
above 1110

T+30 INST POSITIONAL SELL-
| Fut Segment | M&M @ 1370-
1380, TGT- 1280, Closing SL-
above 1430

Key Contents

Result Update

Page No.

4

Nifty Intraday Chart



Market in Retrospect

Indian equity benchmarks held on to steady gains and advanced in trade on Tuesday.

Nifty index ended 0.99% higher, ended at 17,930. The broader markets represented by the Nifty 500 Index ended 0.46% higher, ending at 14,989. Among the sectorial indices, Nifty PSU Bank was the top gainer gaining by 1.04%, followed by Nifty FMCG gaining by 1.03%. Nifty Realty was the top loser losing by 1.84%.

UPL was the top gainer, gaining by 3.79%, followed by ITC and RIL which gaining by 3.27% & 2.36%. Eicher Motors was the top loser, losing by 2.37%, followed by Apollo Hospital and SBI Life losing by 2.06% & 1.48%.

Market Turnover (In Crore) 14-02-2023

Name	Last	Previous
NSE Cash	44624.98	45840.09
NSE F&O	19571146.57	11944019.04
BSE Cash	3,097.74	2,875.80
BSE F&O	115.12	13.64

FII Derivatives Flow (In Crore) 13-02-2023

Instrument	Purchase	Sale	Net
Index Future	3916.55	4837.48	-920.93
Index Option	555276.34	557810.49	-2534.15
Stock Future	9891.99	10478.65	-586.66
Stock Option	11336.00	11474.77	-138.77

Institutional Flow (In Crore) 14-02-2023

Institution	Purchase	Sale	Net
FII	8418.32	7113.02	1305.30
DII	5042.49	4837.70	204.79

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
UPL	3.79	7.38	7326901	1253476
ITC	3.27	3.54	29125052	12621020
RIL	2.36	3.13	6609564	6517437
Adani Ports & SE	2.06	2.16	17976429	26462470
Adani Enterprises	1.87	2.95	14579030	16037350

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Grasim Industries	1.08	0.72	1046887	539404
BPCL	1.12	0.30	1192673	1639454
SBI Life Insurance	1.48	2.65	990530	1932375
Apollo Hospitals	2.06	1.08	339582	297249
Eicher Motors	2.37	3.02	1519235	364887

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 7:30PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	61032.26	600.42	0.99	1.24	1.28	1.36	4.97
Nifty	17929.85	158.95	0.89	1.18	0.15	2.57	3.33
BSE M Cap	24471.96	108.40	0.44	0.67	2.78	3.95	4.59
BSE S Cap	27761.38	170.77	0.61	0.70	3.80	4.46	0.95
Nifty MC 100	30481.80	83.55	0.27	0.59	2.70	2.94	3.77
BSE Auto	30103.10	95.97	0.32	0.47	2.31	0.08	15.07
BSE Capgoods	34603.75	143.50	0.41	0.81	1.33	4.48	21.99
BSE FMCG	16552.10	149.38	0.91	0.45	3.53	3.45	26.28
BSE Metal	20185.52	149.82	0.75	0.13	5.99	0.67	1.04
BSE Oil&Gas	17468.55	14.86	0.08	0.76	15.28	13.37	3.09
BSE Healthcare	22194.89	98.64	0.44	0.07	3.77	6.70	6.95
BSE Power	3432.10	47.00	1.35	3.66	22.50	29.18	10.20
BSE Realty	3208.79	58.67	1.80	2.53	5.63	11.02	10.36
BSE ConsDur	38540.76	99.80	0.26	0.59	0.13	7.67	8.97
BSE Bank	47067.88	395.13	0.85	0.27	2.27	2.74	7.77
BSE IT	30445.90	292.71	0.97	1.09	5.15	1.66	9.53

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.67	0.03	0.87	0.11	4.73	4.78	84.62
UK	3.44	0.03	0.97	3.56	2.05	1.99	116.17
Brazil	6.34	0.03	0.44	2.87	10.10	1.00	24.78
Japan	0.51	0.00	0.20	1.80	0.39	109.02	133.95
Australia	3.74	0.02	0.53	3.98	4.12	0.66	74.88
India	7.37	0.00	0.05	0.34	0.95	1.13	10.55
Switzerland	1.42	0.00	0.14	4.79	26.54	26.76	346.86
Germany	2.38	0.01	0.59	1.41	9.87	10.95	741.70

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.76	0.04	0.04	0.08	1.39	1.81	8.65
USD Index	102.96	0.38	0.37	0.45	0.74	3.47	6.84
YUAN	6.82	0.00	0.04	0.45	1.14	3.72	6.72
GBP	1.22	0.01	0.62	1.38	0.16	3.90	9.71
EUR	1.08	0.00	0.32	0.29	0.60	4.16	4.86
YEN	131.96	0.46	0.35	0.67	2.56	6.01	12.44

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	616.00	14.00	2.33	2.50	34.88	53.51	68.95
Baltic Dirty	1204.00	2.00	0.17	1.15	16.68	36.83	74.49
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34245.93	376.66	1.11	1.05	0.17	2.11	0.93
Nasdaq	11891.79	173.67	1.48	0.04	7.33	6.21	13.77
S&P 500	4137.29	46.83	1.14	0.64	3.46	4.55	6.01
FTSE100	7975.13	27.29	0.34	1.40	1.67	7.99	5.89
CAC40	7241.16	31.40	0.44	1.51	3.08	9.54	5.66
DAX	15464.48	65.61	0.43	0.93	2.50	8.03	2.31
Mexico IPC	53050.83	568.81	1.08	1.85	0.98	2.44	1.37
Brazil Bovespa	109271.5	440.97	0.41	1.34	1.48	3.43	4.06
Russian RTS	954.06	11.58	1.20	4.99	5.55	18.44	33.08
Japan Nikkei	27602.77	175.45	0.64	0.30	5.68	1.38	2.75
Hang Seng	21113.76	50.66	0.24	0.87	2.87	15.10	13.31
Taiwan Index	15654.48	110.20	0.71	1.65	5.60	7.62	12.80
Shanghai Comp	3293.28	9.12	0.28	1.39	3.07	5.08	4.43
KOSPI	2465.64	12.94	0.53	0.57	3.33	0.59	7.88
Malaysia KLCI	1483.97	8.80	0.60	0.51	0.74	2.30	7.23
Jakarta Comp	6941.86	41.72	0.60	0.09	4.52	1.33	1.97
Philippine SE	6791.24	47.52	0.69	1.31	2.31	5.80	7.10
Thai Exch	1652.76	12.13	0.73	1.65	1.72	1.43	2.86

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	79.01	1.15	1.43	2.40	1.09	8.01	17.25
BRENT Crude	85.71	0.91	1.05	2.40	0.18	4.21	2.38
Natural Gas	2.53	0.12	5.11	2.17	20.90	53.27	39.03

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1857.13	6.51	0.35	0.70	3.14	5.00	0.60
Silver(\$/Ounce)	21.77	0.17	0.78	1.58	10.07	0.74	8.48
Aluminium	2378.75	25.99	1.08	4.77	7.31	2.74	24.40
Copper	8916.50	87.74	0.99	0.89	2.75	4.88	9.88
Zinc	3127.00	67.25	2.20	1.17	6.61	2.72	13.64
Lead	2087.50	18.75	0.91	0.01	8.08	3.60	8.71

Agro Commodities

Q3 Performance							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	179.55	2.80	1.58	1.24	17.70	7.71	23.95
Cotton	85.26	0.53	0.62	1.30	3.22	3.35	12.46
Sugar	19.84	0.16	0.81	0.81	7.77	5.59	13.70
Wheat	799.00	1.75	0.22	4.96	6.25	5.92	0.09
Soybean	1532.50	3.50	0.23	1.47	0.34	5.62	9.33

Adani Enterprises

The consolidated profit of Adani Enterprises in the quarter ending December (Q3FY23) was Rs 820 crore improving from a loss of Rs 11.63 crore a year ago. Revenue from operations for the flagship firm of the Adani Group increased 42 per cent to Rs 26,612.23 crore. The net standalone profit in Q3FY23 was Rs 269.71 crore as compared to a loss of Rs 36.46 crore in Q3FY22. It was, however, lower than the net profit of Rs 469.20 crore in Q2FY23. The revenue of the firm was Rs 12,142.15 crore. EBITDA increased by 101 per cent to Rs 1,968 crore.

Apollo Hospitals

Apollo Hospitals Enterprise Ltd posted a decline of 33.3% percent year-on-year in its consolidated net profit for the quarter ended December 31, 2022. Consolidated net profit came at Rs 163.20 crore as against Rs 243.25 crore in the corresponding quarter a year ago. On a sequential basis, the bottomline was down 23.3 percent from Rs 212.8 crore in Jul-Sep. Even as the net profit lagged the Street's estimate of Rs 229.7 crore, the topline managed to top expectations of Rs 4,177.50 crore. The healthcare major's revenue rose 17.2 percent to Rs 4,263.60 crore in the October-December quarter from Rs 3,638.9 crore in the year-ago period. The rise in revenue can be attributed to higher pharmacy sales, better revenue mix, and normalisation of medical tourism. Sequentially, the topline was marginally up from Rs 4,251.10 crore achieved in the previous quarter. Revenue from the digital health and pharmacy segment jumped 34.5 percent on year while that from healthcare services grew around 9 percent. EBITDA margin contracted sharply by 420 basis points to 11.9 percent in the quarter ended December.

Bharat Forge

Net profit of Bharat Forge declined 80.41% to Rs 82.50 crore in the quarter ended December 2022 as against Rs 421.19 crore during the previous quarter ended December 2021. Sales rose 40.03% to Rs 3353.36 crore in the quarter ended December 2022 as against Rs 2394.69 crore during the previous quarter ended December 2021.

Bosch

Auto component major Bosch on its consolidated net profit rose by 36 per cent to Rs 319 crore for the third quarter ended December 31, 2022. The company had reported a net profit of Rs 235 crore in the October-December period of last fiscal. Revenue from operations rose to Rs 3,660 crore in the third quarter as against Rs 3,109 crore in the year-ago period. The company's board declared an interim dividend of Rs 200 per share for the financial year 2022-23 on 29,493,640 shares of Rs 10 each.

Eicher Motors

Net profit of Eicher Motors rose 62.42% to Rs 740.84 crore in the quarter ended December 2022 as against Rs 456.13 crore during the previous quarter ended December 2021. Sales rose 29.62% to Rs 3665.23 crore in the quarter ended December 2022 as against Rs 2827.59 crore during the previous quarter ended December 2021.

Grasim Industries

Net profit of Grasim Industries rose 44.08% to Rs 2515.78 crore in the quarter ended December 2022 as against Rs 1746.14 crore during the previous quarter ended December 2021. Sales rose 17.36% to Rs 28637.86 crore in the quarter ended December 2022 as against Rs 24402.24 crore during the previous quarter ended December 2021.

Harsha Engineers International

Net profit of Harsha Engineers International rose 74.30% to Rs 31.74 crore in the quarter ended December 2022 as against Rs 18.21 crore during the previous quarter ended December 2021. Sales declined 6.95% to Rs 300.68 crore in the quarter ended December 2022 as against Rs 323.14 crore during the previous quarter ended December 2021.

Indiabulls Housing Finance

Net profit of Indiabulls Housing Finance declined 3.96% to Rs 290.97 crore in the quarter ended December 2022 as against Rs 302.97 crore during the previous quarter ended December 2021. Sales rose 2.84% to Rs 2338.99 crore in the quarter ended December 2022 as against Rs 2274.36 crore during the previous quarter ended December 2021.

Ipca Laboratories

The pharmaceutical company's consolidated net profit tumbled 45.25% to Rs 107.84 crore in Q3 FY23 as compared to Rs 196.96 crore reported in Q3 FY22. However, revenue from operations rose 8.08% to Rs 1,546 crore during the quarter as against Rs 1,430.47 crore recorded in the corresponding quarter last year. Total income in Q3 FY23 was at Rs 1,576.89 crore, up by 9% from Rs 1443.40 posted in Q3 FY22. Profit before tax dropped 35.03% year on year to Rs 169.34 crore in the quarter ended 31 December 2022. Total expenses grew 19.01% to Rs 1407.55 crore in Q3 FY23 over Q3 FY22. Cost of materials consumed was at Rs 362.25 crore (down 13.14% YoY) while employee expenses stood at Rs 318.44 crore (up 12.25% YoY). EBITDA before forex declined 15% to Rs 262.82 crore in Q3 FY23 from Rs 310.83 crore posted in Q3 FY22. EBITDA margin reduced to 16.67% in Q3 FY23 as compared with 21.53% reported in the same period last year. The company reported forex gain of Rs 16.07 crore in Q3 FY23 as against forex loss of Rs 9.91 crore recorded in Q3 FY22. Revenue from formulations business stood at Rs 1,102.61 crore in Q3 FY23, up by 11% YoY. During the quarter, income from domestic formulations business rose 9% at Rs 702.25 crore.

La Opala RG

Net profit of La Opala RG rose 6.62% to Rs 34.64 crore in the quarter ended December 2022 as against Rs 32.49 crore during the previous quarter ended December 2021. Sales rose 16.37% to Rs 126.37 crore in the quarter ended December 2022 as against Rs 108.59 crore during the previous quarter ended December 2021.

Nilkamal

Net profit of Nilkamal declined 0.72% to Rs 33.18 crore in the quarter ended December 2022 as against Rs 33.42 crore during the previous quarter ended December 2021. Sales declined 0.28% to Rs 754.29 crore in the quarter ended December 2022 as against Rs 756.40 crore during the previous quarter ended December 2021.

NMDC

NMDC's consolidated net profit more than halved to Rs 903.89 crore for the December quarter, mainly on account of lower income. The company had clocked a net profit of Rs 2,046.88 crore in the October-December period of the preceding 2021-22 fiscal. Its total income also tumbled to Rs 3,924.75 crore from Rs 6,026.68 crore in the year-ago quarter. Total expenses were at Rs 2,693.01 crore, as against Rs 3,332.44 crore a year ago.

Radico Khaitan

Net profit of Radico Khaitan declined 22.62% to Rs 61.23 crore in the quarter ended December 2022 as against Rs 79.13 crore during the previous quarter ended December 2021. Sales rose 4.70% to Rs 792.15 crore in the quarter ended December 2022 as against Rs 756.57 crore during the previous quarter ended December 2021.

Siemens

The industrial manufacturing company's standalone net profit (from continuing operations) surged 80% to Rs 437.6 crore in the quarter ended 31 December 2022 from Rs 243 crore recorded in the quarter ended 31 December 2021. The growth in profit was driven by higher volumes, better price extraction and positive forex & commodity effects. For the first quarter of financial year 2023 ended 31 December 2022, revenue from continuing operations stood at Rs 3,596.2 crore, registering a growth of 17% from Rs 3,069.4 crore recorded in the corresponding quarter previous year. Profit before tax (from continuing operations) jumped 79.8% year on year to Rs 587.6 crore in quarter ended 31 December 2022.

Torrent Power

Torrent Power Ltd reported a 88% year-on-year (YoY) rise in net profit at ₹694.54 crore for the third quarter that ended December 31, 2022. In the corresponding quarter last year, the company posted a net profit of ₹369.45 crore. In the December quarter, total revenue from operations stood at ₹6,442.8 crore during the period under review, up 71% against ₹3,767.4 crore in the corresponding period of the preceding fiscal. the company said its board has approved an interim dividend of ₹22 per equity share (including ₹13 per equity share as a special dividend) for FY 2022-23.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Sundaram-Clayton Ltd	Cash dividend of INR59 effective 03-02-2023
Coforge Ltd	Cash dividend of INR19 effective 03-02-2023
Torrent Pharmaceuticals Ltd	Cash dividend of INR14 effective 03-02-2023
Vedanta Ltd	Cash dividend of INR13 effective 03-02-2023
Motilal Oswal Financial Services Ltd	Cash dividend of INR7 effective 03-02-2023

Domestic Events

- India Balance of Trade for January 2023.

Global Events

- The U.S. Retail Sales, Industrial Production for January 2023.
- Euro Area Balance of Trade and Industrial Production for December 2023.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
